Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline

Klemmer, Anja; Krämer, Irene; Kamin, Wolfgang

Abstract

Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline

Author(s): Klemmer Anja, Krämer Irene, Kamin Wolfgang

Issue: May/Jun 2013 - Volume 17, Number 3

View All Articles in Issue

Page(s): 254-261

Download in electronic PDF format for $75

Abstract

Knowledge of the physicochemical compatibility of admixtures of nebulizable drugs is an important issue. In this article, the results of our recent study dealing with the compatibility of drug admixtures containing budesonide and colistin methanesulfonate (brand name Colistin CF) or budesonide and 5.85% sodium chloride solution are presented, as well as the up-to-date version of our compatibility table. Admixtures were prepared by mixing 2.0 mL Pulmicort either with 3.0 mL Colistin CF or 4.0 mL 5.85% sodium chloride solution. Test solutions were stored for 24 hours at room temperature under ambient light conditions. Physical compatibility was determined by measuring pH and osmolality. Concentrations of budesonide were measured by a high-performance liquid chromatography assay. The antibiotic activity of colistin methanesulfonate was determined in comparison to standard solutions using a microbiological assay. No loss in drug concentration of budesonide and no change in antibiotic activity of colistin methanesulfonate were detected over a test period of 24 hours. Osmolality remained unchanged in both types of admixtures. In admixtures of budesonide with colistin methanesulfonate, pH increased during the first 4 hours of storage, while in admixtures of budesonide and hypertonic saline pH remained unchanged. No visible changes could be detected. Due to these results admixtures of budesonide and colistin methanesulfonate or 5.85% sodium chloride solution are designated to be compatible, but it is recommended that mixing should take place immediately before administration. Further investigations are needed to determine whether or not drug delivery is affected by mixing the drugs and to ensure simultaneous nebulization is recommendable.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2013 Pg. 254-261	Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline Author(s): Klemmer Anja, Krämer Irene, Kamin Wolfgang
May/Jun 2020 Pg. 242-245	Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture Author(s): Ngim Kenley, Patel Jalpa
Mar/Apr 2003 Pg. 106-113	Veterinary Transdermal Medications: A to Z Author(s): Davidson Gigi S
May/Jun 2011 Pg. 190-192	Drug Compatibility and Stability in Dextrose vs Saline Author(s): Newton David W
Sep/Oct 2007 Pg. 426-432	Zinc Content of Commercial Diluents Widely Use in Drug Admixtures Prepared for Intravenous Infusion Author(s): Desai Narendra R, Shah Syed M, Koczone Julianna, Vencl-Joncic Maja, Sisto Christopher, Ludwig Stephen A
May/Jun 2021 Pg. 222-229	Intravenous Admixture Preparation Considerations, Part 9-B: Error Prevention in Intravenous Admixture Preparation Author(s): Allen Loyd V Jr
Mar/Apr 2021 Pg. 131-139	Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 44-50	Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved Author(s): Allen Loyd V Jr
Jul/Aug 2016 Pg. 328-332	Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures Author(s): Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Sep/Oct 2017 Pg. 408	Acetylcysteine Solutions for Inhalation Author(s): Allen Loyd V Jr
Mar/Apr 1997 Pg. 121-122	The Compatibility of Common Respiratory Therapy Drug Combinations Author(s): Owsley Heather D, Rusho William F
Jul/Aug 2001 Pg. 310-312	Wetting and/or Solubilizing Agents, Featured Excipient: Author(s): Allen Loyd V Jr
Jul/Aug 2002 Pg. 311-315	Compatibility Screening of Bivalirudin During Simulated Y-Site Administration with Other Drugs Author(s): Trissel Lawrence A, Saenz Christopher
Jan/Feb 2000 Pg. 58	Morphine Sulfate 2.5-mg/mL Inhalation Solution Author(s): Allen Loyd V Jr
Jul/Aug 1997 Pg. 259	Kennel Cough Inhalation Solutions (Concentrated) Author(s): Allen Loyd V Jr
Nov/Dec 2000 Pg. 455	Flunisolide 0.025% Inhalation Solution (Preservative Free) Author(s): Allen Loyd V Jr
Nov/Dec 2002 Pg. 415-417	Sterile Compounding of Respiratory Inhalation Solutions Author(s): Roberts Rob, Moore Eddie
Mar/Apr 2003 Pg. 133	Albuterol Sulfate 0.5% Inhalation Solution Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 521-525	Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature Author(s): Larson Bayli, Bushman Lane R, Casciano Matthew L, Oldland Alan R, Kiser Jennifer J, Kiser Tyree H
Nov/Dec 2019 Pg. 478-482	Intravenous Admixture Preparation Considerations, Part 1: Overview of Series on Personnel Selection for Intravenous Admixture Compounding Author(s): Allen Loyd V Jr